At the news
? BEARISHIMPACT 4/10 424B5 filed Nov 12, 2026 at 17:21 ET
Fate Therapeutics filed a 424B5 prospectus supplement establishing a new $100M at-the-market (ATM) equity facility with Leerink Partners, replacing a prior ATM with Jefferies. The company had $139.1M in cash as of September 30, 2026 and is a pre-revenue clinical-stage biotech. The ATM provides ongoing capital access for pipeline development but signals continued cash needs.
- ATM facility of up to $100,000,000 in common stock with Leerink Partners as sales agent
- Commission rate of up to 3.0% of gross proceeds
- 106,155 shares already sold under prior ATM for $176,811.77 in gross proceeds
- Last reported sale price on November 11, 2026 was $1.61 per share
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access